Observational studyBMC musculoskeletal disorders2024
Impact of transdermal buprenorphine patch combined with celecoxib on improving shoulder pain and function of patients with primary adhesive shoulder capsulitis.
Observational study in BMC musculoskeletal disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOne of the main purposes of clinical treatment for adhesive shoulder capsulitis is pain relief. However, patients often fail to achieve a satisfactory therapeutic response. This study aims to evaluate the impact of a combination therapy involving buprenorphine transdermal patch and celecoxib capsules on improving shoulder pain and function of patients with primary adhesive shoulder capsulitis (ASC).
methodsThis retrospective observational study consecutively enrolled patients with primary ASC from our hospital Outpatient Department between April 2018 and June 2020. The primary outcome was pain evaluated using the visual analog scale (VAS) score. Secondary outcomes included functional improvement evaluated using the Constant-Murley Shoulder (CMS) score, as well as satisfaction and adverse reactions.
resultsA total of 198 patients were enrolled and categorized into the celecoxib capsule group (n = 72), buprenorphine transdermal patch group (n = 65), and buprenorphine transdermal patch + celecoxib capsule group (n = 61). Patients treated with buprenorphine transdermal patch + celecoxib capsule have the lowest VAS scores and highest CMS scores at 1, 4, 8 and 12 weeks after treatment (all P < 0.001). Furthermore, there were no significant differences in adverse reactions (P = 0.296) among the three groups. The satisfaction of patient with percutaneous buprenorphine transdermal patch + celecoxib capsule was significantly higher than patients with celecoxib capsules or percutaneous buprenorphine transdermal patch (both P < 0.001).
conclusionThe combination of buprenorphine transdermal patch with celecoxib capsule may result in good analgesic efficacy and functional improvement in patients with primary ASC.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.